

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM833974

| | | | |
|---|--|-----------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Entos, Inc. | | 07/11/2023 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | Entos Pharmaceuticals Inc. | | |
| Street Address: | 10230 Jasper Avenue | | |
| Internal Address: | Unit 4550 | | |
| City: | Edmonton, AB | | |
| State/Country: | CANADA | | |
| Postal Code: | T5J4P6 | | |
| Entity Type: | Corporation: CANADA | | |
| PROPERTY NUMBERS Total: 1 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 90894329 | ENTOS | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 5132416234 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 5132412324 | | |
| Email: | tremaklus@whe-law.com | | |
| Correspondent Name: | Theodore R. Remaklus | | |
| Address Line 1: | 600 Vine Street | | |
| Address Line 2: | Suite 2800 | | |
| Address Line 4: | Cincinnati, OHIO 45202 | | |
| ATTORNEY DOCKET NUMBER: | TORYS-102-122 | | |
| DOMESTIC REPRESENTATIVE | | | |
| Name: | Theodore R. Remaklus | | |
| Address Line 1: | 600 Vine Street | | |
| Address Line 2: | Suite 2800 | | |
| Address Line 4: | Cincinnati, OHIO 45202 | | |
| NAME OF SUBMITTER: | Theodore R. Remaklus | | |

OP \$40.00 90894329

| | |
|---|-----------------------|
| SIGNATURE: | /theodore r remaklus/ |
| DATE SIGNED: | 08/23/2023 |
| Total Attachments: 1 source=Trademark Assignment (Entos, Inc. to Ento Pharmaceuticals Inc.)#page1.tif | |

Schedule C**TRADEMARK ASSIGNMENT**

THIS ASSIGNMENT is made effective as of July 11, 2023 between Entos, Inc. (the "Assignor"), a Delaware corporation with its principal place of business at 4470 Sunset Blvd., Ste 107 PMB 94758, Los Angeles, CA, 90027 and Entos Pharmaceuticals Inc. (the "Assignee"), a Canada corporation having its principal place of business at 10230 Jasper Avenue, Unit 4550, Edmonton, Alberta, Canada.

WHEREAS

1. The Assignor is the proprietor of all rights, title and interest in and to US Application No. 90894329 (the "Application").
2. The Assignor has agreed that the right, title, and interest in and to the Application, together with the goodwill of the business symbolized by the Application, will be assigned to the Assignee for good and valuable consideration.

NOW THIS ASSIGNMENT WITNESSES that, for the sum of One Dollar (US\$1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby irrevocably sells, assigns, and transfers to the Assignee all of the Assignor's right, title and interest throughout the world in and to the Application, on an "as-is" basis and without any representations or warranties of any kind (including as to validity, non-infringement or merchantability for any purpose), for all of the goods and/or services included in the relevant application, or in conjunction with which the Application is used, together with the goodwill of the business associated with and symbolized by the Application, and all rights of the Assignee to bring actions, sue for and claim relief in respect of any past, present and future infringement or other violation of rights with respect to the Application (including the right to retain any damages or profits awarded as a result of such action or other proceeding).

The Assignor hereby consents, without any objection, that the Assignee solely request recording of this transfer in any jurisdiction where a recording of this transfer may be effected. The Assignor agrees that, without further consideration, it will cooperate fully with the Assignee in completing any further documents which may be reasonably requested by the Assignee in order to complete the assignment of right, title, and interest to the Application and to more fully and effectively carry out the purposes of this Assignment.

IN WITNESS WHEREOF the Assignor has executed this Assignment on July 11, 2023.

| | |
|--|---|
| Entos, Inc. | Accepted by: Entos Pharmaceuticals Inc. |
| DocuSigned by: By: <u>Mary Anderson</u> 313D678ECDBB43C... | DocuSigned by: By: <u>Jason Ding</u> F1CE0748B046400... |
| Name: Mary Anderson | Name: Jason Ding |
| Position: SVP, Business Development | Position: Chief Business Officer |